{"id":"NCT02886728","sponsor":"Gilead Sciences","briefTitle":"Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy","officialTitle":"A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Na√Øve to MTX Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-08","primaryCompletion":"2018-10-05","completion":"2019-05-08","firstPosted":"2016-09-01","resultsPosted":"2021-01-15","lastUpdate":"2021-06-01"},"enrollment":1252,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Filgotinib","otherNames":["GS-6034","GLPG0634"]},{"type":"DRUG","name":"Placebo to match filgotinib","otherNames":[]},{"type":"DRUG","name":"MTX","otherNames":[]},{"type":"DRUG","name":"Placebo to match MTX","otherNames":[]}],"arms":[{"label":"Filgotinib 200 mg + MTX","type":"EXPERIMENTAL"},{"label":"Filgotinib 100 mg + MTX","type":"EXPERIMENTAL"},{"label":"Filgotinib 200 mg Monotherapy","type":"EXPERIMENTAL"},{"label":"MTX Monotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the effects of filgotinib in combination with methotrexate (MTX) versus MTX alone in adults with active rheumatoid arthritis (RA).","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Filgotinib 200 mg + MTX","deltaMin":81,"sd":null},{"arm":"Filgotinib 100 mg + MTX","deltaMin":80.2,"sd":null},{"arm":"Filgotinib 200 mg Monotherapy","deltaMin":78.1,"sd":null},{"arm":"MTX Monotherapy","deltaMin":71.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG001 vs OG003","p":"0.017"},{"comp":"OG002 vs OG003","p":"0.058"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":186,"countries":["United States","Argentina","Australia","Belgium","Bulgaria","Canada","Chile","Czechia","Germany","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Malaysia","Mexico","New Zealand","Poland","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["38985247","38057656","37747626","36327094","36205910","34980223","34385364","33452004"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":416},"commonTop":["Nausea","Upper respiratory tract infection","Nasopharyngitis","Headache","Hypertension"]}}